Novartis PhII Ceritinib (LDK378) in R/R ALK+ Hem Malignancies

NCT02343679 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped No accrual due to rarity of disease.

Conditions

Hematologic Malignancies

Interventions

DRUG: ceritinib

Sponsor

Anne Beaven, MD

Collaborators

[object Object]